UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2019 Earnings Conference Call - Final Transcript
Aug 12, 2019 • 08:30 am ET
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to UroGen Pharma's Second Quarter 2019 Financial Results and Business Update Conference Call.
It is now my pleasure to turn the call over to Kate Bechtold, Senior Director of Investor Relations for UroGen Pharma. Please go ahead.
Thank you, operator. Good morning, everyone, and welcome to UroGen Pharma's second quarter 2019 financial results and business update conference call. On Friday morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended June 30th, 2019. The press release can be accessed on the Investors portion of our website at investors.urogen.com.
Joining me on the call today are Liz Barrett, President and Chief Executive Officer; Dr. Mark Schoenberg, Chief Medical Officer; and Peter Pfreundschuh, Chief Financial Officer. Joining us for the Q&A portion of this call will be Stephen Mullennix, Chief Operating Officer; and Jeff Bova, Senior Vice President of Commercial. Liz will provide a summary of our recent corporate developments and Mark will share clinical development and regulatory updates. Peter will then provide an overview of our financial highlights for the second quarter of 2019, before we open up the call for questions.
As a reminder, during today's call, we will be making certain forward-looking statements. Various remarks that we make during this call about the Company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements, as a result of various important factors, including those discussed in the Risk Factors section of UroGen Pharma's quarterly report on Form 10-Q filed with the SEC on August 9th and other filings that UroGen Pharma makes with the SEC from time to time. We encourage all investors to read the Company's annual report on Form 10-K and the Company's other SEC filings. These documents are available under the SEC filing section of the Investors page of UroGen's website at investors.urogen.com.
In addition, all information we provide on this conference call represents our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise.
I will now turn the call over to Liz.
Thank you, Kate, and good morning, everyone. We hope you are enjoying this summer and appreciate you taking the time to join our call this morning. Before, we get into the heart of the quarterly call, we're thrilled to announce that on Tuesday, September 24th, we will host our first Investor Day.
The first half of 2019 has set the stage for what is certain to be a pivotal year for UroGen, as we approach key